

Stefano Del Prato

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4975320/stefano-del-prato-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

443 papers	25,031 citations	76 h-index	147 g-index
462 ext. papers	29,046 ext. citations	7.1 avg, IF	6.92 L-index

#	Paper	IF	Citations
443	SIRT1rs7896005 polymorphism affects major vascular outcomes, not all-cause mortality, in Caucasians with Type 2 Diabetes: a 13-year observational study.. <i>Diabetes/Metabolism Research and Reviews</i> , 2022 , e3523	7.5	
442	The IGFBP3/TMEM219 pathway regulates beta cell homeostasis.. <i>Nature Communications</i> , 2022 , 13, 684	17.4	0
441	Basal weekly insulins: the way of the future!. <i>Metabolism: Clinical and Experimental</i> , 2022 , 126, 154924	12.7	2
440	Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 847778	5.7	
439	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.. <i>Diabetes Therapy</i> , 2022 , 13, 847	3.6	2
438	Insulin secretion and action affects glucose variability in the early stages of glucose intolerance.. <i>Diabetes/Metabolism Research and Reviews</i> , 2022 , e3531	7.5	
437	Insulin discovery: A pivotal point in medical history. <i>Metabolism: Clinical and Experimental</i> , 2021 , 127, 154941	12.7	1
436	Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2021 ,	16.7	7
435	COVID-19, Hyperglycemia, and New-Onset Diabetes. <i>Diabetes Care</i> , 2021 , 44, 2645-2655	14.6	32
434	MG53 marks poor beta cell performance and predicts onset of type 2 diabetes in subjects with different degrees of glucose tolerance. <i>Diabetes and Metabolism</i> , 2021 , 48, 101292	5.4	0
433	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. <i>Lancet, The</i> , 2021 , 398, 1811-1824	40	35
432	The incretin/glucagon system as a target for pharmacotherapy of obesity. <i>Obesity Reviews</i> , 2021 ,	10.6	1
431	Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. <i>Diabetes Care</i> 2020;43:e139-e141. <i>Diabetes Care</i> , 2021 , 44, e81	14.6	
430	Impact of COVID-19 lockdown on glucose control of elderly people with type 2 diabetes in Italy. <i>Diabetes Research and Clinical Practice</i> , 2021 , 174, 108750	7.4	14
429	From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021 , 20, 92	8.7	8
428	Diabetes and acute bacterial skin and skin structure infections. <i>Diabetes Research and Clinical Practice</i> , 2021 , 174, 108732	7.4	6
427	Risk factors associated with postpartum impaired glucose regulation in women with previous gestational diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107854	3.2	1

426	Bariatric surgery restores visual cortical plasticity in nondiabetic subjects with obesity. <i>International Journal of Obesity</i> , 2021 , 45, 1821-1829	5.5	0
425	Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1331-1341	6.7	1
424	Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report. <i>Frontiers in Medicine</i> , 2021 , 8, 699477	4.9	0
423	Exercise during pregnancy: how much active are pregnant women at risk of gestational diabetes despite few contraindications?. <i>Gynecological Endocrinology</i> , 2021 , 37, 101-104	2.4	1
422	Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 318-323	6.7	8
421	Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e6-e7	9.5	5
420	Tackling obesity during the COVID-19 pandemic. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , 37, e3393	7.5	2
419	Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 245-251	6.7	1
418	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021 , 64, e7	6	3
417	Predictors of post-traumatic complication of mild brain injury in anticoagulated patients: DOACs are safer than VKAs. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1061-1070	3.7	5
416	Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?. <i>Diabetes Care</i> , 2021 , 44, 647-654	14.6	10
415	Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes. <i>Advances in Therapy</i> , 2021 , 38, 1715-1731	4.1	3
414	Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. <i>Diabetes Care</i> , 2021 , 44, 1062-1069	14.6	9
413	Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future. <i>Diabetes Therapy</i> , 2021 , 12, 2289-2310	3.6	7
412	Use of non-nutritive-sweetened soft drink and risk of gestational diabetes. <i>Diabetes Research and Clinical Practice</i> , 2021 , 178, 108943	7.4	1
411	A fully implantable device for intraperitoneal drug delivery refilled by ingestible capsules. <i>Science Robotics</i> , 2021 , 6,	18.6	5
410	Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: A meta-analysis of observational studies. <i>Diabetes Research and Clinical Practice</i> , 2021 , 180, 109066	7.4	2
409	Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 896-907	59.2	79

408	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 653-662	18.1	58
407	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. <i>Diabetes Care</i> , 2021, 44, 774-780	14.6	2
406	Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 640-648	18.1	94
405	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. <i>Diabetes Care</i> , 2020, 43, 1065-1069	14.6	8
404	New-Onset Diabetes in Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 789-790	59.2	381
403	Review of methods for detecting glycemic disorders. <i>Diabetes Research and Clinical Practice</i> , 2020, 165, 108233	7.4	46
402	Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. <i>Diabetes Care</i> , 2020, 43, 1695-1703	14.6	65
401	Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108112	7.4	8
400	Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1176-1186	6.7	12
399	Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1663-1674	3.9	1
398	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , 2020, 19, 14	8.7	12
397	How conclusive is the CONCLUDE trial?. <i>Diabetologia</i> , 2020, 63, 692-697	10.3	10
396	Nesidioblastosis and Insulinoma: A Rare Coexistence and a Therapeutic Challenge. <i>Frontiers in Endocrinology</i> , 2020, 11, 10	5.7	4
395	Plasma N-Acetylaspartate Is Related to Age, Obesity, and Glucose Metabolism: Effects of Antidiabetic Treatment and Bariatric Surgery. <i>Frontiers in Endocrinology</i> , 2020, 11, 216	5.7	5
394	Impact of disease duration and β -cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1567-1576	6.7	4
393	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154242	12.7	8
392	Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy. <i>Current Medical Research and Opinion</i> , 2020, 36, 555-562	2.5	
391	Reinterpreting Cardiorenal Protection of Renal Sodium-Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming. <i>Diabetes Care</i> , 2020, 43, 501-507	14.6	21

390	Effects of treatment with metformin and/or sitagliptin on beta-cell function and insulin resistance in prediabetic women with previous gestational diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 648-657	6.7	7
389	Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type2 Diabetes. <i>Diabetes Therapy</i> , 2020 , 11, 2465-2476	3.6	4
388	Type 1 diabetes and COVID-19: The "lockdown effect". <i>Diabetes Research and Clinical Practice</i> , 2020 , 170, 108468	7.4	25
387	COVID-19 in people with diabetes: understanding the reasons for worse outcomes. <i>Lancet Diabetes and Endocrinology,the</i> , 2020 , 8, 782-792	18.1	406
386	Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. <i>Diabetes Care</i> , 2020 , 43, 2345-2348	14.6	77
385	Guida pratica alla prevenzione e gestione dell'infezione da COVID-19 nelle persone con diabete. <i>L'Endocrinologo</i> , 2020 , 21, 241-245	0	1
384	Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. <i>Diabetes Care</i> , 2020 , 43, e139-e141	14.6	6
383	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. <i>Diabetologia</i> , 2020 , 63, 2423-2433	10.3	7
382	Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2019 , 394, 1519-1529	40	106
381	Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3296-3302	5.6	8
380	A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2240-2247	6.7	7
379	Exenatide modulates visual cortex responses. <i>Diabetes/Metabolism Research and Reviews</i> , 2019 , 35, e31675	7.5	1
378	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. <i>Diabetes and Vascular Disease Research</i> , 2019 , 16, 399-414	3.3	13
377	Rational combination therapy for type 2 diabetes. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 328-329	18.1	0
376	Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred Approach To IndividualisEd (PROACTIVE) Glycemic Goals for older people: A position statement of Primary Care Diabetes Europe. <i>Primary Care Diabetes</i> , 2019 , 13, 330-352	2.4	14
375	Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome. <i>Journal of the Endocrine Society</i> , 2019 , 3, 496-503	0.4	33
374	Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 252-260	6.7	25
373	Heterogeneity of diabetes: heralding the era of precision medicine. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 659-661	18.1	11

372	Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2564-2569	6.7	7
371	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. <i>Cardiovascular Diabetology</i> , 2019 , 18, 149	8.7	13
370	Inibitori di SGLT-2 e chetoacidosi euglicemica: conoscere per prevenire. <i>L Endocrinologo</i> , 2019 , 20, 336-340	4.0	1
369	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. <i>Diabetes Care</i> , 2019 , 42, 2108-2116	14.6	23
368	Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. <i>Cardiovascular Diabetology</i> , 2019 , 18, 159	8.7	22
367	Altered Visual Plasticity in Morbidly Obese Subjects. <i>IScience</i> , 2019 , 22, 206-213	6.1	9
366	Freestyle Libre trend arrows for the management of adults with insulin-treated diabetes: A practical approach. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 6-12	3.2	13
365	Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 883-892	6.7	11
364	Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 550-557	5.7	7
363	Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2023-2028	6.7	15
362	Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1479-1489	6.7	63
361	Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1542-1546	6.7	9
360	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018 , 1-44	0.1	
359	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2018 , 203, 30-38	4.9	29
358	Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. <i>Atherosclerosis</i> , 2018 , 276, 124-130	3.1	18
357	Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2018 , 17, 78	8.7	4
356	Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2532-2540	6.7	81
355	Type 2 Diabetes Mellitus. From the start to combination therapy. <i>Diabetes Mellitus</i> , 2018 , 21, 386-394	1.6	1

354	Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 786-799	6.7	13
353	Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 55 mg/dl (8.6 mmol/L). <i>Diabetes Research and Clinical Practice</i> , 2018 , 146, 18-33	7.4	44
352	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018 , 392, 1519-1529	4.0	771
351	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018 , 527-569	0.1	
350	Pre-pregnancy obesity, gestational diabetes or gestational weight gain: Which is the strongest predictor of pregnancy outcomes?. <i>Diabetes Research and Clinical Practice</i> , 2018 , 144, 286-293	7.4	25
349	Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. <i>Drugs</i> , 2017 , 77, 247-264	2.4	22
348	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , 2017 , 40, 813-820	14.6	78
347	Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. <i>Diabetologia</i> , 2017 , 60, 1102-1113	10.3	26
346	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations. <i>Obesity Surgery</i> , 2017 , 27, 2-21	3.7	89
345	A Fermented Whole Grain Prevents Lipopolysaccharides-Induced Dysfunction in Human Endothelial Progenitor Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2017 , 2017, 1026268	6.7	15
344	Metabolic regulation of GLP-1 and PC1/3 in pancreatic β cell line. <i>PLoS ONE</i> , 2017 , 12, e0187836	3.7	13
343	Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial. <i>Journal of Diabetes Investigation</i> , 2017 , 9, 579	3.9	8
342	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 887-897	18.1	154
341	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1781-1792	6.7	84
340	Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Reply to Rigalleau V, Blanco L, Alexandre L et al [letter]. <i>Diabetologia</i> , 2017 , 60, 2123-2125	10.3	1
339	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017 , 16, 70	8.7	21
338	Gender difference in diabetes related excess risk of cardiovascular events: When does the 'risk window' open?. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 74-79	3.2	11
337	Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials. <i>Primary Care Diabetes</i> , 2016 , 10, 51-9	2.4	14

336	Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetes-The TOSCA.IT Study. <i>European Journal of Nutrition</i> , 2016 , 55, 1645-51	5.2	32
335	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. <i>Surgery for Obesity and Related Diseases</i> , 2016 , 12, 1144-62	3	96
334	1h post-load blood glucose for detection of individuals at increased risk of diabetes and cardiovascular disease. <i>Diabetes Research and Clinical Practice</i> , 2016 , 120, 184-5	7.4	1
333	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. <i>Cardiovascular Diabetology</i> , 2016 , 15, 111	8.7	40
332	Personalized Therapy by Phenotype and Genotype. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S127-36	14.6	11
331	Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S113-4	14.6	3
330	Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic Ecell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 834-9	6.7	10
329	Hospital incidental diagnosis of diabetes: A population study. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 457-61	3.2	5
328	Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 361-73	4.5	30
327	Beliefs, Barriers, and Preferences of European Overweight Women to Adopt a Healthier Lifestyle in Pregnancy to Minimize Risk of Developing Gestational Diabetes Mellitus: An Explorative Study. <i>Journal of Pregnancy</i> , 2016 , 2016, 3435791	2.5	23
326	Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 886-92	4.5	5
325	Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 623-7	6.7	9
324	Abnormalities of Insulin Secretion and ECell Defects in Type 2 Diabetes 2016 , 161-173		1
323	I nuovi farmaci per il diabete: gli inibitori del co-trasportatore sodio-glucosio di tipo 2 (SGLT-2i). <i>L'Endocrinologo</i> , 2016 , 17, 259-261	0	
322	Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. <i>Diabetes Care</i> , 2016 , 39, 861-77	14.6	522
321	Integrating medical and surgical therapies to optimize the outcomes of type 2 diabetes. <i>Surgery for Obesity and Related Diseases</i> , 2016 , 12, 1186-91	3	4
320	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. <i>Diabetes Care</i> , 2016 , 39, 717-25	14.6	211
319	Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. <i>Postgraduate Medicine</i> , 2016 , 128, 747-754	3.7	4

318	Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015 , 25, 898-905	4.5	45
317	Glucose Metabolism in High-Risk Subjects for Type 2 Diabetes Carrying the rs7903146 TCF7L2 Gene Variant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E1160-7	5.6	11
316	The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 599-606	3.2	15
315	Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. <i>Diabetes, Obesity and Metabolism</i> , 2015 , 17, 581-590	6.7	153
314	Normal Ecell function 2015 , 108-124		2
313	Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. <i>Diabetes Care</i> , 2015 , 38, 2293-300	14.6	35
312	Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy. <i>Diabetes, Obesity and Metabolism</i> , 2015 , 17, 202-6	6.7	25
311	Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. <i>Diabetes, Obesity and Metabolism</i> , 2015 , 17, 1085-92	6.7	71
310	Physical activity, depressed mood and pregnancy worries in European obese pregnant women: results from the DALI study. <i>BMC Pregnancy and Childbirth</i> , 2015 , 15, 158	3.2	24
309	Selective screening for GDM in Italy: application and effectiveness of National Guidelines. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015 , 28, 1842-4	2	15
308	How much weight are women gaining during pregnancy? An Italian cohort study. <i>Gynecological Endocrinology</i> , 2015 , 31, 942-4	2.4	4
307	GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. <i>Acta Diabetologica</i> , 2015 , 52, 1129-33	3.9	12
306	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015 , 38, 193-259	5.2	9
305	Access to emergency room for hypoglycaemia in people with diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2015 , 31, 745-51	7.5	12
304	Effect of diabetes on hospitalization for ischemic stroke and related in-hospital mortality: a study in Tuscany, Italy, over years 2004-2011. <i>Diabetes/Metabolism Research and Reviews</i> , 2015 , 31, 280-6	7.5	13
303	New forms of insulin and insulin therapies for the treatment of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 638-52	18.1	61
302	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72
301	Gender difference in diabetes-associated risk of first-ever and recurrent ischemic stroke. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 713-7	3.2	20

300	Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015 , 17, 107-15	6.7	22
299	Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2015 , 17, 136-44	6.7	21
298	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. <i>Lancet, The</i> , 2014 , 383, 1068-83	40	915
297	Fixed-ratio combination of basal insulin and GLP-1 receptor agonist: is two better than one?. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 856-8	18.1	0
296	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. <i>Diabetes Care</i> , 2014 , 37, 2647-59	14.6	48
295	Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes. <i>Lancet, The</i> , 2014 , 384, 1096	40	2
294	Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. <i>Diabetic Medicine</i> , 2014 , 31, 1178-84	3.5	31
293	Insulin therapy in people with type 2 diabetes: opportunities and challenges?. <i>Diabetes Care</i> , 2014 , 37, 1499-508	14.6	94
292	Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 1111-20	6.7	81
291	Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 560-8	6.7	35
290	Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2014 , 10, 465-75	4.4	8
289	Q192R Paraoxonase (PON)1 Polymorphism, Insulin Sensitivity, and Endothelial Function in Essential Hypertensive Men. <i>Clinical Medicine Insights: Cardiology</i> , 2014 , 8, 57-62	3.2	4
288	Grain and bean lysates improve function of endothelial progenitor cells from human peripheral blood: involvement of the endogenous antioxidant defenses. <i>PLoS ONE</i> , 2014 , 9, e109298	3.7	21
287	Response to comment on Home et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? <i>Diabetes care</i> 2014;37:1499-1508. <i>Diabetes Care</i> , 2014 , 37, e247	14.6	1
286	Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. <i>Journal of Hypertension</i> , 2014 , 32, 951-60	1.9	57
285	Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 1239-46	6.7	57
284	Optimal therapy of type 2 diabetes: a controversial challenge. <i>Aging</i> , 2014 , 6, 187-206	5.6	32
283	Insulin as an early treatment for type 2 diabetes: ORIGIN or end of an old question?. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S198-204	14.6	4

282	PPARG2 Pro12Ala and ADAMTS9 rs4607103 as "insulin resistance loci" and "insulin secretion loci" in Italian individuals. The GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4. <i>Acta Diabetologica</i> , 2013 , 50, 401-8	3.9	26
281	Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013 , 36, 1779-88	14.6	114
280	Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials. <i>Journal of Diabetes and Its Complications</i> , 2013 , 27, 274-9	3.2	13
279	Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 760-6	6.7	33
278	Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 175-84	6.7	259
277	Hyperglycemia and vascular metabolic memory: truth or fiction?. <i>Current Diabetes Reports</i> , 2013 , 13, 403-10	5.6	31
276	Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β -cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 2100-5	5.6	76
275	Pituitary autoimmunity in patients with diabetes mellitus and other endocrine disorders. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 127-31	5.2	9
274	Introduction to the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S111-2	14.6	2
273	Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2013 , 10, 397-409	3.3	30
272	A master course on "Methodologies for bio-medical research in diabetes". <i>Archives of Physiology and Biochemistry</i> , 2013 , 119, 137-8	2.2	
271	Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013 , 6, 161-70	3.4	13
270	Early Detection of Left Ventricular Dysfunction in Diabetes Mellitus Patients with Normal Ejection Fraction, Stratified by BMI: A Preliminary Speckle Tracking Echocardiography Study. <i>Journal of Cardiovascular Echography</i> , 2013 , 23, 73-80	0.6	6
269	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. <i>International Journal of Clinical Practice</i> , 2012 , 66, 731-740	2.9	35
268	Is maternal educational level a risk factor for gestational diabetes in Caucasian women?. <i>Diabetic Medicine</i> , 2012 , 29, 416-7	3.5	7
267	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. <i>Lancet, The</i> , 2012 , 379, 1498-507	40	259
266	Response letter to D. Singh-franco et al. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 1054-5	6.7	
265	Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. <i>Diabetes Technology and Therapeutics</i> , 2012 , 14, 175-82	8.1	39

264	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <i>European Heart Journal</i> , 2012 , 33, 1635-701	9.5	2797
263	'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). <i>European Heart Journal</i> , 2012 , 33, 1635-701	9.5	15
262	Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012 , 22, 997-1006	4.5	36
261	Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance. <i>Diabetes Care</i> , 2012 , 35, 2607-12	14.6	34
260	Might hypovitaminosis D aggravate endothelial dysfunction-related increases in arterial stiffness seen in patients with hypertension and type 2 diabetes? Reply to Boucher BJ [letter]. <i>Diabetologia</i> , 2012 , 55, 3142-3143	10.3	
259	Type 2 diabetes mellitus worsens arterial stiffness in hypertensive patients through endothelial dysfunction. <i>Diabetologia</i> , 2012 , 55, 1847-55	10.3	75
258	Regulation of medical devices used in diabetology in Europe: time for reform?. <i>Diabetologia</i> , 2012 , 55, 2295-7	10.3	10
257	The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 5-14	6.7	342
256	1-Hour OGTT Plasma Glucose as a Marker of Progressive Deterioration of Insulin Secretion and Action in Pregnant Women. <i>International Journal of Endocrinology</i> , 2012 , 2012, 460509	2.7	8
255	The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. <i>Diabetes Care</i> , 2012 , 35, e82	14.6	23
254	Gender effect on the relation between diabetes and hospitalization for heart failure. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2012 , 120, 51-5	2.3	7
253	Evidence for a role of frataxin in pancreatic islets isolated from multi-organ donors with and without type 2 diabetes mellitus. <i>Hormone and Metabolic Research</i> , 2012 , 44, 471-5	3.1	10
252	Glucose and LDL lowering: the need for intensive therapy. <i>Current Vascular Pharmacology</i> , 2012 , 10, 687-93	3.3	1
251	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. <i>Journal of Hypertension</i> , 2012 , 30, 1056-64	1.9	63
250	Long-term (5 years) efficacy and safety of pancreas transplantation alone in type 1 diabetic patients. <i>Transplantation</i> , 2012 , 93, 842-6	1.8	39
249	Metabolic syndrome in subjects at high risk for type 2 diabetes: the genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011 , 21, 699-705	4.5	13
248	Management of type 2 diabetes: new and future developments in treatment. <i>Lancet, The</i> , 2011 , 378, 182-97	4.0	398
247	Results of pancreas transplantation alone with special attention to native kidney function and proteinuria in type 1 diabetes patients. <i>Review of Diabetic Studies</i> , 2011 , 8, 259-67	3.6	27

246	Effect of linagliptin monotherapy on glycaemic control and markers of β -cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 258-67	6.7	259
245	Linagliptin for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2759-62	4	5
244	Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. <i>Diabetes Care</i> , 2011 , 34, 2015-22	14.6	404
243	Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): outcome studies versus clinical experience in the treatment of diabetes. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S99-100	14.6	1
242	Multidrug treatment of type 2 diabetes: a challenge for compliance. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S231-5	14.6	29
241	Circulating endothelial progenitor cells in women with gestational alterations of glucose tolerance. <i>Diabetes and Vascular Disease Research</i> , 2011 , 8, 202-10	3.3	9
240	Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. <i>Diabetes Care</i> , 2011 , 34, 2524-6	14.6	14
239	Metabolic memory and individual treatment aims in type 2 diabetes--outcome-lessons learned from large clinical trials. <i>Review of Diabetic Studies</i> , 2011 , 8, 432-40	3.6	35
238	Glucagon-like peptide-1 secretion in women with gestational diabetes mellitus during and after pregnancy. <i>Journal of Endocrinological Investigation</i> , 2011 , 34, e287-90	5.2	7
237	Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. <i>International Journal of Clinical Practice</i> , 2010 , 64, 295-304	2.9	55
236	Continuous subcutaneous insulin infusion and multiple dose insulin injections in Type 1 diabetic pregnant women: a case-control study. <i>Gynecological Endocrinology</i> , 2010 , 26, 193-196	2.4	12
235	Early left ventricular mechanics abnormalities in prehypertension: a two-dimensional strain echocardiography study. <i>American Journal of Hypertension</i> , 2010 , 23, 405-12	2.3	65
234	Lack of association between CYP21 V281L variant and polycystic ovary syndrome in Italian women. <i>Gynecological Endocrinology</i> , 2010 , 26, 596-9	2.4	3
233	Oxidative stress in response to high glucose levels in endothelial cells and in endothelial progenitor cells: evidence for differential glutathione peroxidase-1 expression. <i>Microvascular Research</i> , 2010 , 80, 332-8	3.7	40
232	G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010 , 20, 22-5	4.5	46
231	A common polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene regulatory region influences MCP-1 expression and function of isolated human pancreatic islets. <i>Transplantation Proceedings</i> , 2010 , 42, 2247-9	1.1	9
230	Functional and survival analysis of isolated human islets. <i>Transplantation Proceedings</i> , 2010 , 42, 2250-1	1.1	5
229	A randomized controlled trial to examine the efficacy and safety of a new super-oxidized solution for the management of wide postsurgical lesions of the diabetic foot. <i>International Journal of Lower Extremity Wounds</i> , 2010 , 9, 10-5	1.6	34

228	Physical activity and dietary habits during pregnancy: effects on glucose tolerance. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010 , 23, 1310-4	2	13
227	Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010 , 17, 73-102	2.9	9
226	2009 SIPREC Consensus Document [Executive Summary. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010 , 17, 237-247	2.9	
225	Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). <i>International Journal of Clinical Practice</i> , 2010 , 64, 160-8	2.9	5
224	Blood glucose control and coronary heart disease. <i>Herz</i> , 2010 , 35, 148-59	2.6	5
223	Serum gamma-glutamyltransferase levels are related to insulin sensitivity and secretion in subjects with abnormal glucose regulation. <i>Diabetes/Metabolism Research and Reviews</i> , 2010 , 26, 181-6	7.5	4
222	The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. <i>Diabetes/Metabolism Research and Reviews</i> , 2010 , 26, 239-44	7.5	90
221	Continuous subcutaneous insulin infusion and multiple dose insulin injections in Type 1 diabetic pregnant women: a case-control study. <i>Gynecological Endocrinology</i> , 2010 , 26, 193-6	2.4	9
220	Changing the treatment paradigm for type 2 diabetes. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S217-22	14.6	27
219	Soluble CD40 ligand levels in essential hypertensive men: evidence of a possible role of insulin resistance. <i>American Journal of Hypertension</i> , 2009 , 22, 1007-13	2.3	9
218	What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. <i>Diabetes and Vascular Disease Research</i> , 2009 , 6, 283-7	3.3	12
217	Genes, diabetes and cardiovascular risk prediction. <i>Nature Reviews Endocrinology</i> , 2009 , 5, 192-3	15.2	
216	Dysglycaemia in non-diabetic hypertensive patients: comparison of the impact of two different classifications of impaired fasting glucose on the cardiovascular risk profile. <i>Journal of Human Hypertension</i> , 2009 , 23, 332-8	2.6	7
215	Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S342-8	14.6	24
214	How do we define cure of diabetes?. <i>Diabetes Care</i> , 2009 , 32, 2133-5	14.6	696
213	Prognostic implications of diabetes phenotyping: new concepts for an old disease. <i>Internal and Emergency Medicine</i> , 2009 , 4, 325-9	3.7	
212	Megatrials in type 2 diabetes. From excitement to frustration?. <i>Diabetologia</i> , 2009 , 52, 1219-26	10.3	102
211	Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. <i>Diabetic Medicine</i> , 2009 , 26, 1185-92	3.5	129

210	Lack of association between TGF-beta-1 genotypes and microalbuminuria in essential hypertensive men. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 1864-9	4.3	11
209	Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009 , 19, 571-9	4.5	33
208	The non-peptidyl low molecular weight radical scavenger IAC protects human pancreatic islets from lipotoxicity. <i>Molecular and Cellular Endocrinology</i> , 2009 , 309, 63-6	4.4	26
207	Serum gamma-glutamyltransferase is not associated to peripheral arterial disease in type 2 diabetic patients: Cross-sectional findings. <i>Atherosclerosis</i> , 2009 , 203, 49-50	3.1	2
206	Effects of exendin-4 on islets from type 2 diabetes patients. <i>Diabetes, Obesity and Metabolism</i> , 2008 , 10, 515-9	6.7	34
205	In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. <i>Diabetic Medicine</i> , 2008 , 25, 326-32	3.5	109
204	The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial. <i>Diabetic Medicine</i> , 2008 , 25, 662-70	3.5	15
203	The metabolic syndrome is related to albuminuria in Type 2 diabetes. <i>Diabetic Medicine</i> , 2008 , 25, 1412-8	3.5	16
202	Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008 , 18, 31-8	4.5	12
201	Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008 , 18, 624-31	4.5	59
200	Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin A preliminary echocardiographic study. <i>Atherosclerosis</i> , 2008 , 197, 346-54	3.1	28
199	Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences. <i>Diabetes and Metabolism</i> , 2008 , 34 Suppl 2, S56-64	5.4	59
198	Highlights from International Congress : The XI Forum on the Renin-Angiotensin System, Capri, Italy, 11-12 April, 2008. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 91-104	2.9	
197	Primary prevention of cardiovascular disease in people with dysglycemia. <i>Diabetes Care</i> , 2008 , 31 Suppl 2, S208-14	14.6	34
196	Early subclinical atherosclerosis in women with previous gestational diabetes mellitus. <i>Diabetes Care</i> , 2008 , 31, e32	14.6	29
195	Insulin resistance and lipid disorders. <i>Future Lipidology</i> , 2008 , 3, 651-664		12
194	Metabolic syndrome and vascular alterations in normotensive subjects at risk of diabetes mellitus. <i>Hypertension</i> , 2008 , 51, 440-5	8.5	49
193	Beneficial effect of the nonpeptidyl low molecular weight radical scavenger IAC on cultured human islet function. <i>Cell Transplantation</i> , 2008 , 17, 1271-6	4	11

192	Peripheral wave reflection and endothelial function in untreated essential hypertensive patients with and without the metabolic syndrome. <i>Journal of Hypertension</i> , 2008 , 26, 1216-22	1.9	19
191	Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. <i>Diabetologia</i> , 2008 , 51, 615-22	10.3	362
190	Beta-cell failure in type 2 diabetes mellitus. <i>Current Diabetes Reports</i> , 2008 , 8, 179-84	5.6	28
189	Optimizing management of metabolic syndrome to reduce risk: focus on life-style. <i>Internal and Emergency Medicine</i> , 2008 , 3, 87-98	3.7	19
188	Modulation of palmitic acid-induced cell death by ergothioneine: evidence of an anti-inflammatory action. <i>BioFactors</i> , 2008 , 33, 237-47	6.1	31
187	Doxazosin in metabolically complicated hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2007 , 5, 1027-35	2.5	6
186	Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 610-4	5.2	46
185	Gestational diabetes, inflammation, and late vascular disease. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 873-9	5.2	24
184	When and how to restore β cell function?. <i>International Congress Series</i> , 2007 , 1303, 138-145		1
183	C-reactive protein and metabolic syndrome in women with previous gestational diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2007 , 23, 135-40	7.5	60
182	Effects of C-peptide on isolated human pancreatic islet cells. <i>Diabetes/Metabolism Research and Reviews</i> , 2007 , 23, 215-9	7.5	15
181	Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. <i>Diabetes/Metabolism Research and Reviews</i> , 2007 , 23, 234-8	7.5	89
180	beta-cell function and anti-diabetic pharmacotherapy. <i>Diabetes/Metabolism Research and Reviews</i> , 2007 , 23, 518-27	7.5	61
179	Pharmacological intervention in prediabetes: considering the risks and benefits. <i>Diabetes, Obesity and Metabolism</i> , 2007 , 9 Suppl 1, 17-22	6.7	9
178	Type 2 diabetes mellitus: focus on new treatments and special populations. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1-2	2.9	1
177	We have the evidence, we need to act to improve diabetes care. <i>International Journal of Clinical Practice</i> , 2007 , 61, 9-15	2.9	6
176	Partnering with governments and other institutions: driving change in diabetes care. <i>International Journal of Clinical Practice</i> , 2007 , 61, 38-46	2.9	2
175	Left ventricular function in normotensive young adults with well-controlled type 1 diabetes mellitus. <i>American Journal of Cardiology</i> , 2007 , 99, 84-90	3	39

174	Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. <i>Journal of Diabetes and Its Complications</i> , 2007 , 21, 20-7	3.2	12
173	Glucose tolerance is negatively associated with circulating progenitor cell levels. <i>Diabetologia</i> , 2007 , 50, 2156-63	10.3	85
172	Coxsackie B4 virus infection of beta cells and natural killer cell insulinitis in recent-onset type 1 diabetic patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 5115-20	11.5	441
171	Treating the metabolic syndrome. <i>Expert Review of Cardiovascular Therapy</i> , 2007 , 5, 491-506	2.5	41
170	Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. <i>Clinical Chemistry</i> , 2007 , 53, 480-8	5.5	127
169	Maternal metabolic control and perinatal outcome in women with gestational diabetes mellitus treated with lispro or aspart insulin: comparison with regular insulin. <i>Diabetes Care</i> , 2007 , 30, e11	14.6	35
168	An off-the-shelf instant contact casting device for the management of diabetic foot ulcers: a randomized prospective trial versus traditional fiberglass cast. <i>Diabetes Care</i> , 2007 , 30, 586-90	14.6	86
167	Correspondence between the International Diabetes Federation criteria for metabolic syndrome and insulin resistance in a cohort of Italian nondiabetic Caucasians: the GISIR database. <i>Diabetes Care</i> , 2007 , 30, e33	14.6	3
166	Normal glucose tolerance and gestational diabetes mellitus: what is in between?. <i>Diabetes Care</i> , 2007 , 30, 1783-8	14.6	55
165	Lack of association between endothelial nitric oxide synthase gene polymorphisms, microalbuminuria and endothelial dysfunction in hypertensive men. <i>Journal of Hypertension</i> , 2007 , 25, 1389-95	1.9	20
164	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. <i>Diabetes and Metabolism</i> , 2007 , 33, 129-34	5.4	100
163	Insulin secretion defects of human type 2 diabetic islets are corrected in vitro by a new reactive oxygen species scavenger. <i>Diabetes and Metabolism</i> , 2007 , 33, 340-5	5.4	36
162	Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2007 , 78, 246-53	7.4	18
161	High insulin levels impair intracellular receptor trafficking in human cultured myoblasts. <i>Diabetes Research and Clinical Practice</i> , 2007 , 78, 316-23	7.4	10
160	Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2155-63	15.9	574
159	Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. <i>Diabetologia</i> , 2006 , 49, 2977-82	10.3	95
158	Cystatin C as a marker of renal function immediately after liver transplantation. <i>Liver Transplantation</i> , 2006 , 12, 285-91	4.5	52
157	The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. <i>European Journal of Endocrinology</i> , 2006 , 154, 355-61	6.5	74

156	Sulfonylureas in the therapy of type 2 diabetes mellitus: where do we stand today?. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, S1	12.7	2
155	The place of sulfonylureas in the therapy for type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, S20-7	12.7	94
154	The metabolic syndrome. Beyond the insulin resistance syndrome. <i>Pharmacological Research</i> , 2006 , 53, 457-68	10.2	11
153	Early impairment of beta-cell function and insulin sensitivity characterizes normotolerant Caucasian women with previous gestational diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006 , 16, 485-93	4.5	8
152	Transcription factors of beta-cell differentiation and maturation in isolated human islets: effects of high glucose, high free fatty acids and type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006 , 16, e7-8	4.5	8
151	The pancreatic beta-cell in human Type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006 , 16 Suppl 1, S3-6	4.5	50
150	Tackling hyperglycemia: a more comprehensive approach. <i>Endocrine Practice</i> , 2006 , 12 Suppl 1, 63-6	3.2	7
149	ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. <i>Endocrine Practice</i> , 2006 , 12 Suppl 1, 6-12	3.2	57
148	ACE gene insertion/deletion polymorphism modulates capillary permeability in hypertension. <i>Clinical Science</i> , 2006 , 111, 357-64	6.5	13
147	Inhaled insulins: the present and future of diabetes therapy. <i>Current Medical Research and Opinion</i> , 2006 , 22, S13-S19	2.5	4
146	Alpha-adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria. <i>Journal of Hypertension</i> , 2006 , 24, 931-7	1.9	16
145	βAdducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria. <i>Journal of Hypertension</i> , 2006 , 24, 1217	1.9	
144	Disappearance of nephrotic syndrome in type 1 diabetic patients following pancreas transplant alone. <i>Transplantation</i> , 2006 , 81, 1067-8	1.8	19
143	Functional and molecular defects of pancreatic islets in human type 2 diabetes. <i>Diabetes</i> , 2005 , 54, 727-35	3.9	366
142	Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005 , 10, 265-72	2.6	16
141	Ninety-five percent insulin independence rate 3 years after pancreas transplantation alone with portal-enteric drainage. <i>Transplantation Proceedings</i> , 2005 , 37, 1274-7	1.1	9
140	Successful solitary pancreas transplantation with portal-enteric drainage following unsuccessful islet cell transplantation. <i>Transplantation Proceedings</i> , 2005 , 37, 1278-9	1.1	
139	Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005 , 15, 250-4	4.5	142

138	Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals. <i>Pharmacological Research</i> , 2005 , 51, 561-5	10.2	9
137	Continually high insulin levels impair Akt phosphorylation and glucose transport in human myoblasts. <i>Metabolism: Clinical and Experimental</i> , 2005 , 54, 1687-93	12.7	27
136	Pathophysiology of Insulin Action in Humans 2005 , 179-197		
135	The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. <i>Coronary Artery Disease</i> , 2005 , 16, 67-73	1.4	19
134	Unlocking the opportunity of tight glycaemic control. Far from goal. <i>Diabetes, Obesity and Metabolism</i> , 2005 , 7 Suppl 1, S1-4	6.7	5
133	Maternal triglyceride levels and newborn weight in pregnant women with normal glucose tolerance. <i>Diabetic Medicine</i> , 2005 , 22, 21-5	3.5	168
132	New-onset diabetes after kidney transplantation. <i>Diabetic Medicine</i> , 2005 , 22, 1125-6	3.5	4
131	Effects of pancreas-kidney transplantation on diabetic retinopathy. <i>Transplant International</i> , 2005 , 18, 619-22	3	72
130	Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. <i>International Journal of Clinical Practice</i> , 2005 , 59, 1345-55	2.9	97
129	Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. <i>International Journal of Clinical Practice</i> , 2005 , 59, 1309-16	2.9	35
128	Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. <i>Journal of Diabetes and Its Complications</i> , 2005 , 19, 60-4	3.2	66
127	Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. <i>Diabetologia</i> , 2005 , 48, 282-9	10.3	260
126	Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. <i>Diabetes Care</i> , 2005 , 28, 982-3	14.6	41
125	Hepatitis C virus infection and human pancreatic beta-cell dysfunction. <i>Diabetes Care</i> , 2005 , 28, 940-1	14.6	85
124	The beneficial effects of pancreas transplant alone on diabetic nephropathy. <i>Diabetes Care</i> , 2005 , 28, 1366-70	14.6	74
123	Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells. <i>Endocrinology</i> , 2004 , 145, 2845-57	4.8	57
122	Rosiglitazone plus metformin: combination therapy for Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 1411-22	4	12
121	Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones. <i>Diabetes Technology and Therapeutics</i> , 2004 , 6, 719-31	8.1	13

120	Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 5535-41	5.6	268
119	Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickening. <i>Diabetes and Vascular Disease Research</i> , 2004 , 1, 51-2	3.3	3
118	Increased O-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic beta-cells. <i>FASEB Journal</i> , 2004 , 18, 959-61	0.9	67
117	Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2153-9	5.6	68
116	Serum haptoglobin: a novel marker of adiposity in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2678-83	5.6	99
115	Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 2397-402	2.4	62
114	Lack of evidence for the 1484insG variant at the 3'-UTR of the protein tyrosine phosphatase 1B (PTP1B) gene as a genetic determinant of diabetic nephropathy development in type 1 diabetic patients. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 2419-20	4.3	0
113	Low-grade inflammation and microalbuminuria in hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 2414-9	9.4	74
112	The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets. <i>European Journal of Endocrinology</i> , 2004 , 151, 207-14	6.5	20
111	Beta-cell mass plasticity in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2004 , 6, 319-31	6.7	32
110	What does postprandial hyperglycaemia mean?. <i>Diabetic Medicine</i> , 2004 , 21, 208-13	3.5	97
109	A simplified technique for the en bloc procurement of abdominal organs that is suitable for pancreas and small-bowel transplantation. <i>Surgery</i> , 2004 , 135, 629-41	3.6	55
108	Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance. <i>Diabetologia</i> , 2004 , 47, 300-3	10.3	95
107	Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. <i>Diabetes/Metabolism Research and Reviews</i> , 2004 , 20, 246-51	7.5	19
106	Beta- and alpha-cell dysfunction in type 2 diabetes. <i>Hormone and Metabolic Research</i> , 2004 , 36, 775-81	3.1	88
105	Pancreas transplant alone. <i>Transplantation Proceedings</i> , 2004 , 36, 569-70	1.1	6
104	Solitary pancreas transplantation: preliminary findings about early reduction of proteinuria in incipient or evident diabetic type I nephropathy. <i>Transplantation Proceedings</i> , 2004 , 36, 591-6	1.1	4
103	Kidney and pancreas transplants in Jehovah's witnesses: ethical and practical implications. <i>Transplantation Proceedings</i> , 2004 , 36, 601-2	1.1	13

102	An alternative and simple method to consistently prepare viable isolated human islets for clinical transplantation. <i>Transplantation Proceedings</i> , 2004 , 36, 605-6	1.1	5
101	Portal enteric-drained solitary pancreas transplantation without surveillance biopsy: is it safe?. <i>Transplantation Proceedings</i> , 2004 , 36, 1090-2	1.1	4
100	Simultaneous pancreas-kidney transplantation is improved by living kidney donation program. <i>Transplantation Proceedings</i> , 2004 , 36, 1061-3	1.1	1
99	Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation. <i>Transplantation Proceedings</i> , 2004 , 36, 1064-6	1.1	6
98	Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome. <i>Atherosclerosis</i> , 2004 , 172, 383-9	3.1	56
97	Pancreas preservation with University of Wisconsin and Celsior solutions: a single-center, prospective, randomized pilot study. <i>Transplantation</i> , 2004 , 77, 1186-90	1.8	64
96	Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARGgamma2 in the modulation of insulin secretion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004 , 286, E560-7	6	114
95	The extracellular portion of the insulin receptor beta-subunit regulates the cellular trafficking of the insulin-insulin receptor complex. Studies on Chinese hamster ovary cells carrying the Cys 860-->Ser insulin receptor mutation. <i>European Journal of Endocrinology</i> , 2003 , 148, 365-71	6.5	3
94	Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. <i>Diabetes Care</i> , 2003 , 26, 2075-80	14.6	49
93	Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: effects of pressure relief. <i>Diabetes Care</i> , 2003 , 26, 3123-8	14.6	100
92	Microalbuminuria, a parameter independent of metabolic influences in hypertensive men. <i>Journal of Hypertension</i> , 2003 , 21, 1163-9	1.9	10
91	Solitary pancreas transplantation in Wolfram syndrome. <i>Transplantation</i> , 2003 , 76, 1535-6	1.8	1
90	Pancreas transplant alone determines early improvement of cardiovascular risk factors and cardiac function in type 1 diabetic patients. <i>Transplantation</i> , 2003 , 76, 974-6	1.8	37
89	In situ protein Kinase C activity is increased in cultured fibroblasts from Type 1 diabetic patients with nephropathy. <i>Diabetologia</i> , 2003 , 46, 524-30	10.3	17
88	Hyperglycaemia and cardiovascular risk. <i>Acta Diabetologica</i> , 2003 , 40 Suppl 2, S362-9	3.9	12
87	Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. <i>Acta Diabetologica</i> , 2003 , 40, 20-7	3.9	22
86	Identification of cathepsin K as a novel marker of adiposity in white adipose tissue. <i>Journal of Cellular Physiology</i> , 2003 , 195, 309-21	7	60
85	Intermediate metabolism in normal pregnancy and in gestational diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2003 , 19, 259-70	7.5	215

84	Elevated non-esterified fatty acids impair nitric oxide independent vasodilation, in humans: evidence for a role of inwardly rectifying potassium channels. <i>Atherosclerosis</i> , 2003 , 169, 147-53	3.1	18
83	Prevalence and risk factors for gestational diabetes assessed by universal screening. <i>Diabetes Research and Clinical Practice</i> , 2003 , 62, 131-7	7.4	128
82	Type 2 diabetes management: putting theory into practice--introduction. <i>Metabolism: Clinical and Experimental</i> , 2003 , 52, 1-2	12.7	
81	Type 2 diabetes: simple, dual or multiple pathogenetic defects?. <i>International Congress Series</i> , 2003 , 1253, 95-103		
80	Reducing insulin resistance with metformin: the evidence today. <i>Diabetes and Metabolism</i> , 2003 , 29, 6S28-35	9.4	152
79	Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus. <i>Molecular Diagnosis and Therapy</i> , 2003 , 3, 355-8		9
78	A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. <i>Diabetes</i> , 2003 , 52, 1280-3	0.9	114
77	A telemedicine support for diabetes management: the T-IDDM project. <i>Computer Methods and Programs in Biomedicine</i> , 2002 , 69, 147-61	6.9	94
76	Universal screening and intensive metabolic management of gestational diabetes: cost-effectiveness in Italy. <i>Acta Diabetologica</i> , 2002 , 39, 69-73	3.9	19
75	Use of new ADA and WHO criteria for the diagnosis of impaired fasting glycemia and diabetes in kidney graft recipients. <i>Acta Diabetologica</i> , 2002 , 39, 129-30	3.9	1
74	In search of normoglycaemia in diabetes: controlling postprandial glucose. <i>International Journal of Obesity</i> , 2002 , 26 Suppl 3, S9-17	5.5	62
73	Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. <i>Diabetes</i> , 2002 , 51, 1437-42	0.9	501
72	Concomitance of diabetic retinopathy and proteinuria accelerates the rate of decline of kidney function in type 2 diabetic patients. <i>Diabetes Care</i> , 2002 , 25, 2026-31	14.6	45
71	Early improvement of unstable diabetic retinopathy after solitary pancreas transplantation. <i>Diabetes Care</i> , 2002 , 25, 2358-9	14.6	25
70	Insulin secretory function is impaired in isolated human islets carrying the Gly(972)-->Arg IRS-1 polymorphism. <i>Diabetes</i> , 2002 , 51, 1419-24	0.9	96
69	Lipotoxicity in human pancreatic islets and the protective effect of metformin. <i>Diabetes</i> , 2002 , 51 Suppl 1, S134-7	0.9	130
68	Phasic insulin release and metabolic regulation in type 2 diabetes. <i>Diabetes</i> , 2002 , 51 Suppl 1, S109-16	0.9	154
67	Biochemical and ultrasound tests for early diagnosis of active neuro-osteoarthropathy (NOA) of the diabetic foot. <i>Diabetes Research and Clinical Practice</i> , 2002 , 58, 1-9	7.4	24

66	Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. <i>European Journal of Clinical Investigation</i> , 2001 , 31, 603-9	4.6	64
65	The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2001 , 17, 164-74	7.5	155
64	Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2001 , 51, 97-105	7.4	12
63	Continuous subcutaneous insulin infusion in a patient with partial endocrine pancreatic graft function. <i>Transplantation Proceedings</i> , 2001 , 33, 3500-1	1.1	
62	Cardiovascular risk factors in recipients of successful kidney-pancreas transplantation. <i>Transplantation Proceedings</i> , 2001 , 33, 3681	1.1	
61	Glucose intolerance and diabetes in recipients of kidney graft: comparison of old and new ADA and WHO criteria. <i>Transplantation Proceedings</i> , 2001 , 33, 3664	1.1	
60	Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR). <i>European Journal of Clinical Investigation</i> , 2000 , 30, 45-52	4.6	84
59	Brain function rescue effect of lactate following hypoglycaemia is not an adaptation process in both normal and type I diabetic subjects. <i>Diabetologia</i> , 2000 , 43, 733-41	10.3	54
58	Mechanisms of acute and chronic hypoglycemic action of gliclazide. <i>Acta Diabetologica</i> , 2000 , 37, 201-6	3.9	10
57	Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 793-8	5.6	62
56	Effects of glucosamine infusion on insulin secretion and insulin action in humans. <i>Diabetes</i> , 2000 , 49, 926-35	0.9	122
55	Left ventricular mass in type 2 diabetes mellitus. A study employing a simple ECG index: the Cornell voltage. <i>Journal of Endocrinological Investigation</i> , 2000 , 23, 139-44	5.2	5
54	Effect of acute ketosis on the endothelial function of type 1 diabetic patients: the role of nitric oxide. <i>Diabetes</i> , 1999 , 48, 391-7	0.9	18
53	Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. <i>Diabetes</i> , 1999 , 48, 1316-22	0.9	83
52	Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. <i>Diabetes</i> , 1999 , 48, 99-105	0.9	132
51	Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man. EGIR (European Group for the Study of Insulin Resistance). <i>International Journal of Obesity</i> , 1999 , 23, 1307-13	5.5	46
50	Measurement of insulin resistance in vivo. <i>Drugs</i> , 1999 , 58 Suppl 1, 3-6; discussion 75-82	12.1	21
49	Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. <i>Circulation</i> , 1998 , 98, 234-41	16.7	132

48	Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. <i>Diabetes</i> , 1998 , 47, 1347-1353	0.9	23
47	Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance. <i>Diabetologia</i> , 1997 , 40, 687-97	10.3	76
46	Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. <i>Diabetes</i> , 1997 , 46, 1040-1046	0.9	28
45	Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 1996 , 45, 1196-202	12.7	12
44	High blood ketone body concentration in type 2 non-insulin dependent diabetic patients. <i>Journal of Endocrinological Investigation</i> , 1996 , 19, 99-105	5.2	34
43	Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals. <i>Journal of Clinical Investigation</i> , 1996 , 98, 108-15	15.9	63
42	Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 2332-9	4	61
41	Insulin resistance and diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 1996 , 10, 243-5	3.2	31
40	Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996 , 81, 1568-1574	5.6	32
39	Ethanol impairs insulin-mediated glucose uptake by an indirect mechanism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996 , 81, 2285-2290	5.6	21
38	Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. <i>Diabetes</i> , 1996 , 45, 915-925	0.9	39
37	Insulin sensitivity is not impaired in Mexican-American women without a family history of diabetes. <i>Diabetes Care</i> , 1995 , 18, 825-33	14.6	7
36	What therapy do our NIDDM patients need? Insulin releasers. <i>Diabetes Research and Clinical Practice</i> , 1995 , 28 Suppl, S159-65	7.4	7
35	Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. <i>Diabetes</i> , 1995 , 44, 165-172	0.9	38
34	Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin. <i>Diabetes Care</i> , 1994 , 17, 535-40	14.6	4
33	Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. <i>Diabetologia</i> , 1994 , 37, 1025-35	10.3	248
32	Body composition study in the elderly: comparison between tritium dilution method and dual photon absorptiometry. <i>Journal of Gerontology</i> , 1993 , 48, M244-8		8
31	Short-term effects of metformin on insulin sensitivity and sodium homeostasis in essential hypertensives. <i>Journal of Hypertension</i> , 1993 , 11, S276-???S277	1.9	5

30	Mechanisms of fasting hypoglycemia and concomitant insulin resistance in insulinoma patients. <i>Metabolism: Clinical and Experimental</i> , 1993 , 42, 24-9	12.7	22
29	Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. <i>Journal of Clinical Investigation</i> , 1993 , 91, 484-94	15.9	128
28	Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. <i>Journal of Clinical Investigation</i> , 1993 , 92, 486-94	15.9	118
27	In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension. <i>Diabetes</i> , 1993 , 42, 764-772	0.9	7
26	Retrospective analysis of daily glucose profile in type 1 diabetic patients with continuous subcutaneous insulin infusion (CSII). <i>Diabetes Research and Clinical Practice</i> , 1992 , 16, 197-202	7.4	1
25	The contribution of hyperglycaemia and hypoinsulinaemia to the insulin resistance of streptozotocin-diabetic rats. <i>Diabetologia</i> , 1992 , 35, 310-5	10.3	40
24	Hepatic sensitivity to insulin: effects of sulfonylurea drugs. <i>American Journal of Medicine</i> , 1991 , 90, 29S-36S	10.4	10
23	Rationale for the association of sulfonylurea and insulin. <i>American Journal of Medicine</i> , 1991 , 90, 77S-82S	10.4	5
22	Glucose turnover and recycling in diabetes secondary to total pancreatectomy: effect of glucagon infusion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 70, 1023-9	5.6	17
21	Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents. <i>Diabetologia</i> , 1990 , 33, 688-95	10.3	24
20	Insulin regulation of glucose and lipid metabolism in massive obesity. <i>Diabetologia</i> , 1990 , 33, 228-36	10.3	54
19	Obesity and insulin resistance in humans: a dose-response study. <i>Metabolism: Clinical and Experimental</i> , 1990 , 39, 452-9	12.7	290
18	'Do-it-yourself' insulin pump. Case report. <i>Acta Diabetologica Latina</i> , 1989 , 26, 75-8		1
17	Metabolic control during total parenteral nutrition: use of an artificial endocrine pancreas. <i>Metabolism: Clinical and Experimental</i> , 1988 , 37, 510-3	12.7	14
16	The combined treatment with insulin and sulfonylurea in non-insulin-dependent diabetic patients with secondary failure. Rationale and guidelines. <i>Diabetes Research and Clinical Practice</i> , 1988 , 4 Suppl 1, 75-81	7.4	4
15	Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. <i>Diabetes Care</i> , 1987 , 10, 62-7	14.6	96
14	Insulin receptors on circulating blood cells from patients with pancreatogenic diabetes: a comparison with type I diabetes and normal subjects. <i>Journal of Endocrinological Investigation</i> , 1987 , 10, 311-9	5.2	10
13	Hyperglucagonemia and insulin-mediated glucose metabolism. <i>Journal of Clinical Investigation</i> , 1987 , 79, 547-56	15.9	74

12	Hyperalaninaemia is an early feature of diabetes secondary to total pancreatectomy. <i>Diabetologia</i> , 1985 , 28, 277-81	10.3	7
11	Effects of insulin treatment on ketone body production and carnitine-palmitoyl-transferase (CPT) activity in the isolated perfused liver from streptozotocin diabetic rats. <i>Hormone and Metabolic Research</i> , 1985 , 17, 271-4	3.1	3
10	Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor. <i>Journal of Endocrinological Investigation</i> , 1984 , 7, 111-5	5.2	
9	Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy. <i>Diabetologia</i> , 1983 , 25, 252-9	10.3	24
8	Metabolic effects of moderate alcohol intake with meals in insulin-dependent diabetics controlled by artificial endocrine pancreas (AEP) and in normal subjects. <i>Metabolism: Clinical and Experimental</i> , 1983 , 32, 463-70	12.7	15
7	The presence of retinopathy in patients with secondary diabetes following pancreatectomy or chronic pancreatitis. <i>Diabetes Care</i> , 1983 , 6, 570-4	14.6	34
6	Insulin resistance in Cushing's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983 , 57, 529-36	13.2	
5	The relationship between alanine and ketone body in vivo. <i>Metabolism: Clinical and Experimental</i> , 1982 , 31, 1175-8	12.7	10
4	Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. <i>Diabetes</i> , 1982 , 31, 346-355	9	12
3	The antiketogenic effect of alanine in normal man: evidence for an alanine-ketone body cycle. <i>Metabolism: Clinical and Experimental</i> , 1981 , 30, 563-7	12.7	21
2	Glycerophosphate acetyltransferase activity in perfused liver of normal and hyperlipemic rats: glucagon effect. <i>Acta Diabetologica</i> , 1981 , 18, 357-63	3.9	4
1	Glucagon levels and ketogenesis in human diabetes following total or partial pancreatectomy and severe chronic pancreatitis. <i>Acta Diabetologica Latina</i> , 1980 , 17, 111-8		14